4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape. Looking towards the future, what advancements do you anticipate in the treatment ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback